We will screen lung cancer cell lines for EGFR lung cancer mutations and correlate with drug resistance. We hypothesize that some mutations are sensitive to the drug and some are resistant. We will verify these mutations in patient fine needle aspirate samples, allowing physicians to provide better treatment.